An Open-label Study Adding Creatine Monohydrate To Ongoing Medical Regimens In Patients With The Fibromyalgia Syndrome
Notes for this study:
||Although there was a statistically significant improvement in Pittsburg Sleep Quality (PSQI) scores, the lack of a control group and small sample size make it difficult to ascertain the clinical significance of these improvements. Mean and SD. PSQI scores, range 0-21. Baseline: 7.82 ± 3.60. Maximum improvement during treatment: 6.25 ± 3.49. End of follow up: 5.39 ± 2.51. Significance of trend during 12-week study: p = 0.16. Baseline vs maximum improvement: p = 0.006. Maximum improvement vs. end of follow up: p = 0.04
|Number of Subjects
In this 8-week non-controlled trial, 30 people with fibromyalgia were given 3 g of creatine (in 1000 mg tablets) for 3 weeks, which was then increased to 5 g daily for the remaining 5 weeks. Measurements of symptoms of fibromyalgia, quality of life, sleep, disability, and pain were done at baseline, at 4 weeks, after the 8 week intervention, and 4 weeks after the intervention.
Although there were improvements in all of the primary measures, these improvements were not found at the 4 week follow up assessments.
It is important to note that only 12 of the 30 participants were assessed for the final analysis, as the rest of the participants either withdrew, not able to comply with the intervention or were lost to follow-up.